NCT03932045 is a NA clinical trial of SYB Filler (SF-01) in Nasolabial Folds, sponsored by Samyang Biopharmaceuticals Corporation.

Who is sponsoring NCT03932045?

NCT03932045 is sponsored by Samyang Biopharmaceuticals Corporation.

What drugs are being tested in NCT03932045?

Interventions in NCT03932045: SYB Filler (SF-01), Ellansé M.

What condition does NCT03932045 study?

NCT03932045 studies Nasolabial Folds.

Is NCT03932045 still recruiting?

NCT03932045 is currently completed. Last updated 22 November 2022.

Last reviewed 2022-11-22 · How we verify

NCT03932045

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety and Efficacy of SYB Filler(SF-01) in the Correction of Nasolabial Folds

Completed NA Last updated 22 November 2022

What this trial tests

NA trial testing SYB Filler (SF-01) in Nasolabial Folds in 59 participants. Completed in 12 August 2022.

Timeline

8 October 2018

Primary endpoint
15 September 2020

12 August 2022

Quick facts

Lead sponsor	Samyang Biopharmaceuticals Corporation
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	59
Start date	8 October 2018
Primary completion	15 September 2020
Estimated completion	12 August 2022
Sites	1 location across South Korea

Drugs / interventions tested

SYB Filler (SF-01)
Ellansé M

Conditions studied

Nasolabial Folds — all drugs for Nasolabial Folds →

Sponsor

Samyang Biopharmaceuticals Corporation — full company profile →

Who can join

Adults 20 to 70, any sex, with Nasolabial Folds. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this clinical trial is to verify the safety and efficacy of SYB Filler (SF-01) in the temporary improvement of Nasolabial Folds.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Samyang Biopharmaceuticals Corporation trials

Trials by the same sponsor.

NCT07467239 — A Prospective Clinical Investigation of DMFI300 for Treating Nasolabial Folds · NA · recruiting
NCT06961448 — A Study in Adults Evaluating Polycaprolactone Microsphere Filler for Treatment of Moderate to Severe Nasolabial Folds · NA · not yet recruiting
NCT06402058 — A Study Comparing DMSB01 and Rejuran® for Temporary Crow's Feet Lines Improvement · NA · not yet recruiting
NCT06295172 — A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement · NA · not yet recruiting
NCT06093321 — A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03932045 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samyang Biopharmaceuticals Corporation
Last refreshed: 22 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932045.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing